Ranbaxy, Sun race to generic Razadyne

Who's first out of the gate on a generic Razadyne? Indian drug maker Ranbaxy announced today that it got the FDA's tentative nod for its version of the dementia treatment--but so did Sun Pharmaceuticals, also of India. Ranbaxy also said it "anticipates" the 180-day exclusive marketing window automatically awarded to first-dibs generics makers. No word, however, from the FDA on which company actually will win that privilege.

Ranbaxy says it expects final approval for its version in December 2008. Annual sales of Razadyne, made by Ortho-McNeil, now amount to $130 million.

- see this release from Ranbaxy
- here's the news on Sun's announcement from Moneycontrol

Related Articles:
FDA backlog slows generic drug approval. Report
Ranbaxy reportedly near $100M generics deal. Report
Pfizer, Ranbaxy get mixed ruling in Lipitor patent fight. Report
Patent 'cliff' looms for Big Pharma. Report